Member

Cytonus Therapeutics, Inc.


Cytonus Therapeutics is pioneering the convergence of artificial intelligence and synthetic biology to revolutionize drug development and delivery. The company challenges the high failure rates of traditional and precision medicines by developing next-generation therapeutics that are both highly effective and safe. Their mission is to create pragmatic shifts in how drugs are designed and administered, focusing on precision, safety, and efficacy to improve patient outcomes.

Industries

biotechnology
health-care
medical

Nr. of Employees

small (1-50)

Cytonus Therapeutics, Inc.


Products

Enucleated synthetic cell delivery platform

A synthetic biology delivery platform composed of pre-programmed, enucleated cell-like entities designed to home to diseased tissue after intravenous administration and locally produce biologic therapeutics.

Expertise Areas

  • AI-driven drug discovery
  • Synthetic biology delivery platform development
  • Targeted drug delivery
  • In situ biologic production
  • Show More (2)

Key Technologies

  • Machine learning for therapeutic design
  • Synthetic enucleated cell engineering
  • Targeted drug-delivery platforms
  • In situ biologic production
  • Show More (2)

Key People

Remo Moomiaie

CEO and cofounder

LinkedIn

News & Updates

Cytonus has received funding from eight grants and support from industry-leading biotech investors, reflecting strong confidence in their innovative approach and technology.

An article detailing the science and innovation behind Cytonus' targeted drug delivery platform, highlighting the transition from conceptual science to real-world application.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.